XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:        
Revenues $ 373,000 $ 0 $ 373,000 $ 0
Operating expenses:        
Research and development 4,727,000 4,205,000 10,401,000 9,159,000
General and administrative 1,575,000 1,580,000 3,220,000 3,185,000
Total operating expenses 6,302,000 5,785,000 13,621,000 12,344,000
Operating loss (5,929,000) (5,785,000) (13,248,000) (12,344,000)
Other income (expense):        
Foreign exchange gains (losses) (76,000) 209,000 (161,000) 238,000
Interest income 77,000 17,000 193,000 21,000
Other income (expense), net (106,000)   58,000 1,280,000
Total other income (expense), net (105,000) 226,000 90,000 1,539,000
Loss before taxes (6,034,000) (5,559,000) (13,158,000) (10,805,000)
Income tax benefit 586,000 984,000 1,906,000 2,122,000
Net loss (5,448,000) (4,575,000) (11,252,000) (8,683,000)
Dividend on convertible exchangeable preferred shares (50,000) (50,000) (101,000) (101,000)
Net loss applicable to common shareholders $ (5,498,000) $ (4,625,000) $ (11,353,000) $ (8,784,000)
Basic and diluted earnings per common share:        
Net loss per share - basic $ (0.44) $ (0.46) $ (0.91) $ (0.87)
Net loss per share - diluted $ (0.44) $ (0.46) $ (0.91) $ (0.87)
Weighted average common shares outstanding basic 12,551,794 10,136,089 12,545,526 10,065,007
Weighted average common shares outstanding diluted 12,551,794 10,136,089 12,545,526 10,065,007
Clinical trial supply        
Revenues:        
Revenues $ 373,000   $ 373,000